Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042991 · ClinicalTrials.gov registry record · Phase 1
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT00042991: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00042991 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 69 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00042991, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may make the tumor cells more sensitive to radiation therapy. This phase I/II trial is studying how well giving gefitinib together with radiation therapy works in treating children with newly diagnosed glioma.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- RADIATION radiation therapy
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2002-07 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00042991
The ClinicalTrials.gov registry entry for NCT00042991 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00042991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00042991 about?
NCT00042991 is a clinical study titled "Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas". Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may make the tumor cells more sensitive to radiation therapy. This phase I/II trial is studying how well giving gefitinib together with radiation therapy works in treating children with newly diagnosed glioma...
What is the current status of trial NCT00042991?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2002-07. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00042991?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), radiation therapy (RADIATION), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00042991?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.